Publications
Sort:
Open Access Letter Issue
Glofitamab vs. real-world regimens in Chinese patients with third- or later-line relapsed/refractory diffuse large B-cell lymphoma: an external control study
Cancer Biology & Medicine 2025, 22(10): 1218-1222
Published: 30 September 2025
Abstract PDF (225 KB) Collect
Downloads:20
Total 1